You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

 

Online download statistics by month:

Online download statistics by month: September 2020 to September 2025

AbstractFullPdf
Sep 2020411411172
Oct 202025625663
Nov 202012312342
Dec 202011511532
Jan 202117417457
Feb 202128728738
Mar 202125825866
Apr 202117017032
May 202117817824
Jun 202115315324
Jul 202113713717
Aug 202114914924
Sep 202113913927
Oct 202115115160
Nov 202116916844
Dec 202114114328
Jan 202212712921
Feb 202214514728
Mar 202215615741
Apr 202214114236
May 202210010526
Jun 202211111326
Jul 2022848614
Aug 202210510516
Sep 2022979724
Oct 2022909328
Nov 2022676716
Dec 202243449
Jan 202394949
Feb 2023848415
Mar 2023828318
Apr 2023546023
May 2023838330
Jun 2023687013
Jul 2023636328
Aug 2023545413
Sep 2023494911
Oct 2023444410
Nov 202310110113
Dec 202318918916
Jan 2024293013
Feb 2024373717
Mar 2024555558
Apr 2024566225
May 2024646425
Jun 2024666525
Jul 2024949625
Aug 2024595715
Sep 2024696921
Oct 2024707016
Nov 2024444521
Dec 2024495214
Jan 2025595919
Feb 2025434420
Mar 2025444415
Apr 2025848520
May 2025484828
Jun 2025424521
Jul 2025110
Sep 2025110
Total625663001632